Advanced Filters
noise

melanoma Clinical Trials

A listing of melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 463 clinical trials
T Tanja Mesti

Biomarkers in Immunotherapy of Melanoma

Background: Immunotherapy has been successful in treating advanced melanoma, but a large proportion of patients do not respond to the treatment with immune checkpoint inhibitors (ICIs). Preclinical and small cohort studies suggest biomarkers from the primary tumor, stool and body fluids as markers of response. This prospective study will evaluate …

18 years of age All Phase N/A
N Neelam Lal

Axitinib + Ipilimumab in Advanced Melanoma

The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma.

18 years of age All Phase 2
M Meghan Mooradian, MD

Cryoablation+Ipilimumab+Nivolumab in Melanoma

The aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is resistant, or is growing, after receiving immunotherapy with a PD-1 inhibitor. The names of …

18 years of age All Phase 2
R Rino Seedor, MD

Neoadjuvant Tebentafusp for Uveal Melanoma

This phase II trial tests how well tebentafusp works to shrink tumors prior to primary treatment with surgery or radiation in patients with uveal (eye) melanoma that has spread to nearby tissue or lymph nodes (locally advanced) or that cannot be removed by surgery (unresectable). Tebentafusp is a drug that …

18 years of age All Phase 2
J Joanna Ludzik, MD

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

This trial studies how well MoleMapper, Visiomed, and confocal microscopy work in screening participants for melanoma. Analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.

18 - 80 years of age All Phase N/A
S Shaheer Khan, MD

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation …

18 years of age All Phase 1/2
R Recruitment Department

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

The purpose of this pilot study will be to provide i) information on feasibility implementing an exercise intervention trial among patients with cutaneous cancers, including melanoma, squamous cell carcinoma (cuSCC), and Merkel cell carcinoma, scheduled to receive checkpoint blockade immunotherapy, and ii) preliminary data on the impact of a day-of-therapy …

18 years of age All Phase N/A
P Patrick A Ott, MD

NeoVax + CDX-301 and Nivolumab in Melanoma

This research study is studying the drugs called NeoVax (a new type of personalized neoantigen vaccine) in combination with CDX-301 and Nivolumab as a possible treatment for melanoma. The names of the study drugs involved in this study are: Personalized Neoantigen peptides (which combined with poly-ICLC make the vaccine NeoVax) …

18 years of age All Phase 1

Immune Profiles Evolution Under Immunotherapy for Melanoma

The primary objective of the study aims to compare the immune profiles (circulating cytokines and lymphocytes) before and after (6 to 8 weeks) the first infusion of immune checkpoint inhibitors in patients with melanoma treated in the adjuvant setting(cohort A) or in metastatic setting(cohort B); and to study the association …

18 years of age All Phase N/A
Y Yvonne Taul

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose dabrafenib and trametinib regimen for patients with metastatic or unresectable melanoma carrying a BRAF V600 mutation and have relapsed on a BRAF/MEK inhibitor therapy. The goal is to assess the toxicity and tolerability and determine the maximum …

18 years of age All Phase 1

Simplify language using AI